|Bid||4.35 x 500|
|Ask||5.10 x 100|
|Day's Range||4.45 - 4.94|
|52 Week Range||0.50 - 7.49|
|PE Ratio (TTM)||-2.81|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.
NEW YORK, NY / ACCESSWIRE / June 13, 2017 / Shares of Xbiotech saw a nice rebound in Monday trading, gaining back roughly half of what it lost this past Friday when an independent data monitoring committee ...
GTx, Inc. today announced release of preliminary clinical data from its ongoing, open-label, Phase 2 clinical trial of enobosarm 3 mg in postmenopausal women with stress urinary incontinence .